MEI Pharma Recommends Stockholders Not to Consent
Files Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson...
Stay updated with breaking news from Consent Revocation Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Files Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson...
MEI Pharma, Inc. , a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan ("Rights Plan")...
MEI Pharma, Inc. today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The MEI Board of Directors...
Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to...
s Independent financial analysts widely recognize this progress: “ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.” 2 “By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.” 3 “We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12)...ZIOP has executed well over 2020 in curating immune receptors from its own libra...